Semaglutide for weight loss in advanced interstitial lung

Build status - In Progress

Recruiting

18 years - 99 years

All

Phase N/A

10 participants needed

1 Location

Brief description of study

The aim of the pilot study is to demonstrate feasibility and tolerability of semaglutide in patients with obesity and advanced ILD.

Detailed description of study

Semaglutide is a antidiabetic medication that has been known to help with long-term weight-loss management. The aim is to see the tolerability of the medication in patients with ILDs to promote weight-loss for feasibility of further pulmonary treatment. This is a 22-week study, during which you will be asked to work with the research study team and meet with them to complete research procedures.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Medical Research,Interstitial Lung Disease,Obesity
Age: 18 years - 99 years
Gender: All

- Diagnosis of an Interstitial Lung Disease

- BMI > 35 kg/m²

- Requires supplemental oxygen on exertion

- Semaglutide prescribed by primary pulmonologist

- Insurance approval

Updated on 04 Aug 2024. Study ID: 851742

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

View email

Phone

View phone

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.